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Summary
Genomics and whole genome sequencing (WGS) have the
capacity to greatly enhance knowledge and understanding of
infectious diseases and clinical microbiology. The growth and
availability of bench-top WGS analysers has facilitated the
feasibility of genomics in clinical and public health micro-
biology. Given current resource and infrastructure limitations,
WGS is most applicable to use in public health laboratories,
reference laboratories, and hospital infection control-afﬁliated
laboratories. As WGS represents the pinnacle for strain
characterisation and epidemiological analyses, it is likely to
replace traditional typing methods, resistance gene detection
and other sequence-based investigations (e.g., 16S rDNA
PCR) in the near future. Although genomic technologies are
rapidly evolving, widespread implementation in clinical and
public health microbiology laboratories is limited by the need
for effective semi-automated pipelines, standardised quality
control and data interpretation, bioinformatics expertise, and
infrastructure.
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BACKGROUND
Advances in technology, including the rapidly growing field of
genomics, are transforming clinical medicine. The term ‘geno-
mics’ was first coined in 1986 by Dr Thomas Roderick, a
geneticist in Bar Harbour, Maine, and was initially intended as
a term to encompass the study and comparison of genomes of
various species, including their evolution and relationships.1
Essentially, genomics involves the application of DNA sequen-
cing and the subsequent analyses using in vitro experiments and
bioinformatic approaches to study the structure and function of
genes, both human and pathogen.
In recent decades, genomics has been used extensively in a
research capacity to study infectious agents, with the develop-
ment of high throughput ‘next-generation’ sequencing technol-
ogies allowing detailed large scale analyses of entire pathogen
genomes. However, despite the perceived benefits of sequen-
cing technology to support traditional methods in diagnostic
microbiology, there has been limited application in clinical and
public health laboratories in Australasia to date.
This review aims to examine applications of current tech-
nologies in diagnostic microbiology and to outline the added
value and current limitations of genomics, and in particular,
bacterial whole genome sequencing (WGS), in order to support
microbiologists in future implementation and use of these new
technologies in clinical and public health practice.
WGS: METHODS, SEQUENCING TECHNOLOGY
AND DATA ANALYSIS
The evolution of sequencing technology
The Human Genome Project instigated a revolution in sequen-
cing technologies resulting in the establishment of high-
throughput WGS as an important tool for the study of organ-
isms, both human and microbial. Initial technological advances
focussed on enhancing the chain termination sequencing
method published by Sanger et al. in 1977.2 These modifi-
cations included fluorescent labelling of molecules, develop-
ment and utilisation of capillary-based instruments, and
automation of these processes to allow analysis of multiple
samples in parallel.3
As Sanger sequencing was limited to <1000 bases, the
search for more efficient methods for sequencing long, com-
plex pieces of DNA such as entire chromosomes, led to other
approaches. Initially described in 1979, ‘shotgun sequencing’,
where longer segments of DNAwere randomly fragmented into
smaller segments for Sanger sequencing, was an early step
towards facilitating genome sequencing, but was slow and
labour-intensive for an entire genome, requiring a map to
assemble the sequenced fragments.4 With the parallel advance-
ments in computation technology and software, this strategy
evolved into ‘whole-genome shotgun sequencing’, which
bypassed the need for a genetic map by using bacterial clones
to produce a large amount of redundant sequence read data
across the genome and utilising newer computation technology
to assemble the sequence reads. This method resulted in the
landmark sequencing of the Haemophilus influenzae genome,5
the first genome from a free-living organism to be sequenced,
and was the most popular and advanced sequencing method
until the late 2000s.6
Next-generation sequencing
More recently, the invention of high-throughput ‘next-gener-
ation’ sequencing technology, with relatively simple benchtop
technology and efficient library preparation protocols, has
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significantly improved the capacity to perform low-cost, effi-
cient WGS, and has made it a feasible tool to enhance clinical
diagnostic investigations in near real-time. Next-generation
processes generally involve parallel sequencing, producing
vast quantities of data that require modern computation
methods to assemble the sequence reads.
Figure 1 shows the typical workflow and application of next-
generation sequencing that could be applied to clinical micro-
biology.
There are a number of commercialised next-generation
sequencing methods in use and novel technologies emerging
onto the market, each with advantages and disadvantages,
which have been reviewed in detail previously,6–12 although
several are now outdated with the rapid growth in technology.
While this review is not exhaustive, a summary of the current
most common sequencing technology is shown in Tables 1–3.
Sequencing options for clinical microbiology: what needs
to be considered?
There are a number of important considerations in comparing
sequencing platforms for clinical microbiology, and deciding
whether to perform in-house sequencing or to out-source to an
experienced sequencing service provider.
Cost
The cost of implementation including equipment set up, routine
sequencing costs for reagents and consumables as well as post-
processing bioinformatics costs is an obvious, but significant
factor. These expenses can be measured in cost per sequencing
run, cost per organism genome sequenced, or cost per megabase
of output data. To be a financially viable option for clinical
microbiology laboratories WGS must be able to replace current
technologies (e.g., methods for molecular characterisation of
pathogens such as pulsed field gel electrophoresis), or provide
additional benefits in patient outcomes and clinical or labora-
tory efficiency.
In-house versus outsourced
In-house sequencing may improve turnaround times for data
generation and analyses, however this requires significant
investment in technology and data analysis expertise. Although
outsourcing may result in longer turnaround times, it may
improve overall time and cost efficiency of sequencing by
pooling isolates from smaller laboratories with insufficient
sample numbers to fill a standard sequencing run. However,
clear communication between referrer and provider is para-
mount to ensure that the clinical questions to be answered with
WGS are clear, and that the subsequent analysis is understood
and verified by both parties.
Sequencing capacity
Some available technologies allow sequencing a handful of
bacterial genomes in a few hours, while others have capacity to
sequence 50–100 bacterial genomes in a single run that may
take between 1 and 3 days. Flexibility in sequencing through-
put, without significant financial implications of cost per
sample, should also be considered. A reference microbiology
laboratory needs to be able to sequence a large collection of
50–100 samples for epidemiological purposes, but also have
the ability to sequence a small number of strains of pathogens of
public health concern urgently for a similar cost per sample.
Adaptability
Adaptability of the sequencing platform to upgrades and chan-
ging sequencing practices is another factor, with sequencing
technology rapidly evolving. The capability of the sequencer to
be used for human genome sequencing and for research groups
may also allow sharing of resources in smaller centres with
lower demand for microbial WGS.
Data quality
The quality of a sequence result can be reported using a score to
indicate the quality and accuracy of each nucleotide base call.
Genomic
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Whole genome
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eg. lllumina MiSeq Short reads
Read mapping to a reference
genome and SNP calling
De novo assembly
Local alignment
Epidemiologic comparisons and
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Gap closure and finishing
Contigs
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Fig. 1 Whole genome sequencing workﬂow. (1) DNA extraction from homogeneous microbial samples, e.g., single bacterial colony from a pure culture. (2) Whole
genome sequencing using next-generation sequencers. Most high-throughput sequencers produce short reads (e.g., Illumina MiSeq), although long reads from Paciﬁc
Biosciences RS II or Illumina TruSeq technology may facilitate de novo assembly more readily. (3) SNPs called from read mapping to a reference genome can be used for
phylogenetic comparisons to assist in epidemiological and outbreak analyses. Reads can also be assembled de novo into longer contiguous sequences (contigs), and
orientated and aligned to form scaffolds. (4) The resulting de novo assemblies can be used for further analyses such as typing and resistance detection based on local
alignment tools (e.g., BLAST), or can be further ﬁnished into a completed or closed genome. This ﬁnishing stage usually requires gap closure through extensive ‘wet-lab’
techniques such as primer walking, and so is generally performed for research purposes, althoughWGS long reads are increasingly being used to produce more complete
de novo assemblies and minimise the amount of laboratory work required. (5) Data analysis for outbreak investigation, typing, or resistance detection. Closed annotated
genomes can be used as reference genomes for comparison, or can be analysed in further detail.
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For example, Illumina uses a Phred-score (see Appendix 1:
Glossary, http://links.lww.com/PAT/A30), with a score of 20
(Q20) equating to 1 error every 100 bases, or a 1% error rate,
while a score of 30 (Q30) indicates an error rate of 1 every 1000
bases (0.1%). Modern WGS methods aim to achieve a quality
score of 30 across the genome, although sequencing for differ-
ent purposes may have different targets.
Despite the differences between sequencing platforms, in
experienced hands, the output from several of the established
next-generation sequencers (Tables 2 and 3) appears to be
sufficient for most current clinical applications.13 The potential
advantages of long sequence reads for clinical microbiology are
still being investigated,14 although in a research environment,
long reads (>5000 bp) have helped overcome many of the
limitations of short read data.15,16 Examples include resolution
of tandem repeat units and insertion sequences, identification of
smaller circularised sequences such as plasmids, and bridging
contiguous sequence gaps that litter de novo assemblies from
short reads to assist with genome closure. Although this may
soon become the standard in bacterial genome sequencing, the
advantages are offset by the lower throughput, and higher
implementation and sequencing costs, with other sequencers
producing output data of sufficient quality and resolution for
clinical purposes.
Bioinformatic analysis of sequencing data
With the technological advances in generating large amounts of
high quality sequencing data, the bottleneck in implementing
whole genome sequencing for clinical purposes has shifted to
the post-sequencing data analysis. The term ‘bioinformatics’
encompasses the handling and analysis of sequencing data,
usually with the assistance of computer-based algorithms.
Although both ‘open source’ and commercially available
bioinformatic programs/tools have been specifically developed
for use in a clinical setting by clinicians with limited bioinfor-
matics knowledge,17–20 many of these lack the ability to batch
Table 1 Popular sequencing technology
Traditional sequencing
Sanger sequencing  Still widely used for sequencing short segments of DNA (up to 1000 bp) due to the ease and accuracy of sequencing
 Labour, time and cost intensive for sequencing entire genomes on a regular basis
Shotgun sequencing  Involved fragmentation of long strands of DNA into numerous smaller segments for Sanger sequencing
 Facilitated initial whole genome sequencing efforts
 Shotgun approach still utilised by ’next-generation’ sequencing methods
Next-generation sequencing technologies
Pyrosequencing (Roche 454)  Detects pyrophosphate release on addition of a complementary nucleotide to determine the template sequence
 Lower throughput and subsequently higher sequencing cost per base
 One of the earlier next-generation technologies, but now being phased out with Roche intending to cease
production in 2016
SOLiD sequencing (Life Technologies)  Sequencing by Oligonucleotide Ligation and Detection (SOLiD) uses a ligation-based approach
 Less popular than Life Technologies’ other platform, the Ion Torrent, and likely to be superseded by newer
technologies
Ion semiconductor sequencing
(Life Technologies Ion Torrent)
 Uses a sequencing-by-synthesis method, detecting changes in pH due to hydrogen ion release with synthesis of
complementary DNA
 Popular due to lower sequencer cost and speed of sequencing
 Requires separate emulsion PCR library ampliﬁcation prior to sequencing (slow and complicated), though
automation can be performed using the separate Ion Chef system
 Higher error rates, particularly homopolymers, than other platforms and poor coverage of extremely AT-rich or
GC-rich regions
 Ion Torrent Personal Genome Machine (PGM) and newer, higher throughput Ion Proton available
Illumina sequencing  Uses a sequencing-by-synthesis method, detecting release of ﬂuorescent labels from incorporated nucleotides to
determine sequence
 Current market leader with high sequence throughput, with low error rate and low sequencing cost per base
 Limitations of short read sequences and a longer sequencing run time
 Several platforms with moderate (MiSeq), moderate-high (NextSeq) and high (HiSeq) throughput
 TruSeq long read technology recently introduced to produce synthetic reads of 10 kb in length (currently only
HiSeq 2000/2500)
Single molecule real-time sequencing
(Paciﬁc Biosciences)
 Novel method – observes natural synthesis of unmodiﬁed DNA by DNA polymerase, with reads up to 40 kb in
length, using nucleotides with ﬂuorescent labels attached to the terminal phosphate (rather than the base)
 Higher raw error rates, but errors are randomly distributed (vs. ends of reads or homopolymers), and overlapping
reads can produce a consensus sequence with high accuracy
 Has signiﬁcantly improved de novo assembly and bacterial genome completion without needing traditional
PCR-based gap closure
 High setup cost and low throughput have limited implementation, though outsourcing options are available
Emerging technologies
Nanopore sequencing (Oxford Nanopore)  Probably the leader of the pack of benchtop sequencing technologies in development
Detects characteristic disruptions in a current applied across a protein channel or ’nanopore’ as each nucleotide of a
strand of DNA is passed through the nanopore
 Method still being reﬁned, but has the capability of generating long-sequence reads
 Two portable/affordable benchtop sequencers available – the MinION (disposable USB stick), and the GridION
(rack-mountable)
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analytical processes on large datasets and customise auto-
mation of data analysis pipelines, as a trade-off for the ease
of use via a graphical user interface (GUI). The majority of
available bioinformatic software requires some knowledge of
the text-based command-line of the UNIX or Linux operating
systems, allowing custom programming scripts and pipelines to
automate data manipulation and analysis in a single step.
Table 4 shows examples of bioinformatics tools commonly
employed for analysis of bacterial genomes.
In assessing bioinformatics software for analysis of WGS
data for clinical microbiology, there are several considerations
and criteria to take into account.
Useability
Although Linux-based tools will continue to predominate due
to the ability and ease in customising analyses, tools that can be
operated through a GUI may be preferred by those unfamiliar
with bioinformatics.
Automation
Another key advantage of Linux-based tools, although often
requiring some initial work to establish, is a ‘pipeline’ for
specific types of analyses. These pipelines enable ‘batching’
or sequential running of a number of processes on multiple
genomes with a single command, compared with running each
component individually, before manually entering the next
command.
Speed
In a clinical setting, the ability to obtain a result quickly is often
a priority over correcting minor inaccuracies in single nucleo-
tide polymorphism (SNP) calls that do not change the overall
result. Bioinformatic tools that are able to analyse multiple
samples together and utilise the processing power and resources
of modern computers to split large complex processes into
smaller processes running in parallel exemplify the ‘many
hands make light work’ proverb, a feature known as multi-
threading or hyperthreading.
Accuracy and detail
It naturally follows that the accuracy of the analysis is import-
ant for clinical microbiology, particularly for organism identi-
fication, typing, and resistance detection. However, while
research pursuits require accurate and detailed analyses, the
additional resolution from this level of detail is not always
required for clinical decisions. For example, in inferring
Table 2 Comparison of popular next-generation sequencers: benchtop sequencing platforms for low-moderate throughput
Illumina MiSeq
Ion Torrent PGM
(Life Technologies)
Ion Proton
(Life Technologies)
Roche 454 GS
Junior
Conﬁguration Nextera Reagent Kit v3 Ion 318TM Chip v2 Proton I chip GS Junior Plus
Dimensions 69 57 52 cm 61 51 53 cm 54 78 47 cm 40 60 40 cm
Weight 54.5 kg 30 kg 59 kg 25 kg
Preparation time 8 hours 8 hours 8 hours 8 hours
Sequencing time 60 hours 4–7 hours 2–4 hours 18 hours
Data output (Gb per run) 13–16 Gb/run 600 Mb – 2 Gb/run 10 Gb/run 50–70 Mb/run
Sequence read length 2 300 bp 200 / 400 bp 200 bp 700 bp
Number of S. aureus
(2.9 Mb genome)
per run at 30x coverage
75 15 60 1 (at 15x coverage)
Error rate* Overall 0.1% Overall 0.5–2.5% Not reported Overall 0.2–1.0%
Indel error rate 0.001
per 100 bp
Indel error rate
1.5 per 100 bp
Indel error rate
0.4 per 100 bp
Accuracy Mostly Q30 Mean Q20 (Q10-Q30) Not reported Q20-Q30
Cost of platform
(approximate){
$150,000 $100,000 $150,000 $100,000
Advantages  Higher accuracy and
data output
 Low cost per output
 Library ampliﬁcation
incorporated
 Low platform cost
 Short run time
 Low cost per output
 Rapid run time
 Smaller instrument size
 Longer read length
(up to 800 bp with
GS Juniorþ)
Disadvantages  Longer run time
 Higher platform cost
 Shorter read length
 Requires separately ampliﬁed
sequence libraries by emPCRz
 Higher indel error rate,
particularly with homopolymers
 Quality of sequence deteriorates
at ends of reads, though can be
improved with post-sequencing
read clipping
 Poor coverage of AT-rich
regions
 Can be more difﬁcult to
assemble
 Requires separately
ampliﬁed sequence
libraries by emPCRz
 Higher indel error rate,
particularly with
homopolymers
 Quality of sequence
deteriorates at ends of reads,
though can be improved
with post-sequencing read
clipping
 Poor coverage of AT-rich
regions
 Can be more difﬁcult to
assemble
 More ’hands-on’ time –
requires manually
ampliﬁed sequence
libraries by emPCR
 Higher indel error rate,
particularly with
homopolymers
 Higher cost per output
 Requires manually
ampliﬁed sequence
libraries
 Roche closing sequencing
operations and ceasing
production
* Based on Loman et al.7 and Ju¨nemann et al.9
{Costs are only approximate at time of writing, and may vary substantially – intended only as a rough guide.
z emPCR¼ emulsion PCR. Slow and complicated process; automated ampliﬁcation systems are available for Ion Torrent/Ion Proton (Ion Chef).
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phylogenetic relationships between organisms, Bayesian
methods have become popular in estimating a phylogenetic
tree. However, while substantially faster neighbour-joining
methods may not produce as accurate an evolutionary tree,
the resolution is likely to be sufficient and rapid enough for
analysing a public health outbreak in real time, where the
organisms involved are highly clonal.
Cost
Although there is a large amount of free publicly available
software for bioinformatic analysis, these tend to be command-
line based with low adaptability across different sequencing
platforms. GUI-based software that can be used with relatively
little experience is available, though often at a cost, both
financial as well as speed and occasionally detail. For example,
Applied Maths Bionumerics suite offers a wide range of tools
for analysis at a cost of approximately AU$17 per isolate.
Galaxy is a free, open source web-based platform for bioinfor-
matics, but requires data uploading and sharing of public
servers, which limit the speed of analyses.
Documentation and support
An advantage of commercial software is the availability of user
manuals and professional support for troubleshooting. In
contrast, while there is usually some documentation for use
and limited support available from open-source software devel-
opers, many issues require local computing expertise for
implementation and troubleshooting.
Public genome data
A number of public repositories of sequencing data are
available, with published sequences available for download
for comparative genomic analysis. The National Center for
Biotechnology Information’s (NCBI) GenBank database
currently lists just over 3000 annotated complete genome
assemblies in addition to 25,000 draft genome assemblies.
The NCBI genome data are exchanged with the European
Molecular Biology Laboratory’s (EMBL) European Nucleo-
tide Archive and the DNA Data Bank of Japan (DDBJ),
which together form the International Nucleotide Sequence
Database Collaboration. The Global Microbial Identifier
initiative (http://www.globalmicrobialidentifier.org/) is
another independent collaboration that aims to coordinate a
microbial sequencing data collection and collate the collec-
tive genomic and metadata to facilitate subsequent analysis
on a global scale, although the data are only available
to collaborators.
Table 3 Comparison of popular next-generation sequencers: high-end sequencing platforms for high throughput/long reads
Illumina HiSeq 2500 Illumina NextSeq 500 Roche 454 GS FLXþ Paciﬁc Biosciences RS II
Conﬁguration Rapid-run mode
Dual ﬂow-cell
High output ﬂow cell Titanium XLþ RS II
Dimensions 119 76 94 cm 59 53 64 cm Upper 74 70 36 cm 200 77 158 cm
Lower 75 91 93 cm
Weight 221 kg 83 kg 242 kg 1091 kg
Preparation time 8 hours 8 hours 8 hours 8 hours
Sequencing time 60 hours 30 hours 24 hours 4 hours
Data output (Gb per run) 250–300 Gb/run 100–120 Gb/run 0.7 Gb/run 0.5–1 Gb/run
Sequence read length 2 250 bp* 2 150 bp 700 bp 1,000–40,000 bp{
Number of S. aureus
(2.9 Mb genome)
per run at 30x coverage
1200z 480z 5 1
Error rate 0.1% 0.1% 0.2–1.0% 14%§
Accuracy Mostly Q30 Mostly Q30 Q20-Q30 Mostly Q30
Cost of platformjj $650,000 $250,000 $500,000 $750,000
Advantages  Massive throughput
(though better suited
to human genome
sequencing)
 Low cost per output
 High output and rapid
run modes
 High throughput
suitable for microbial
genomes
 Lower instrument cost
 Low cost per output
 Dimensions suitable
for ‘benchtop’
 Potential for
expansion/upgrades
 Read length up to
1000 bp facilitates
de novo assembly
 Long reads facilitate de novo
assembly and resolution of repetitive
genomic regions
 Able to sequence regions of high GC
content (results in more uniform
coverage of the genome)
 Detects modiﬁed DNA bases, eg,
DNA methylation patterns
Disadvantages  Longer run time
 Short reads limit
de novo assembly*
 Higher instrument cost
 Short reads limit
de novo assembly
 More ‘hands-on’ time
– requires manually
ampliﬁed sequence
libraries by emPCR
 Higher cost per output
 Roche closing sequencing
operations and ceasing
production
 Lower output
 Higher error rate in individual reads§
 Higher instrument cost and cost
per output
 Large instrument size
* TruSeq Long Read technology allows sequencing reads of 10,000 bp in length.
{N50¼ 14,000 bp; i.e., half of the sequence data is contained in reads >14,000 bp.
zTheoretical number for comparison only – requires custom-synthesised indices. Current Illumina Index Kits (Nextera XT) allow up to 384 samples per ﬂow
cell.
§Error rate is based on raw read error rate. However, as the error model for SMRT sequencing is stochastic, combining reads can produce high quality consensus
sequence across all bases. Our experience is that in comparison with sequencing on the Illumina MiSeq, the RS II produces high quality consensus sequences
with an error rate approximately 1 per 1000 bases (predominantly homopolymers).
jjCosts are only approximate at time of writing, and may vary substantially – intended only as a rough guide
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PERSPECTIVES ON GENOMICS IN CLINICAL
MICROBIOLOGY
We recently conducted a qualitative online survey of infectious
diseases physicians, microbiologists and other professionals
involved in the management of infectious diseases on attitudes
towards bacterial whole genome sequencing in Australia and
New Zealand. Of 102 respondents, 74% were either clinical
microbiologists or infectious diseases physicians, with the
remaining 26% either infectious diseases/microbiology trainees
Table 4 Common software for bioinformatic analysis
De novo assembly
 De novo assembly involves using computer algorithms to align overlapping WGS reads to form longer contiguous sequences known as contigs, and order the
contigs into a framework of the sequenced genome (scaffolds). Velvet (https://www.Ebi.Ac.Uk/zerbino/velvet/)72 and SPAdes (http://bioinf.Spbau.Ru/spades)73
are two of the more popular assemblers for Illumina short-reads, while Ion Torrent reads are better assembled using MIRA (http://www.Chevreux.Org/projects_
mira.Html). Other commonly used assemblers include Newbler (http://swes.Cals.Arizona.Edu/maier_lab/kartchner/documentation/index.Php/home/docs/
newbler) for 454 pyrosequencing reads, and the commercial CLC Genomics suite. Assemblers used for PacBio long reads include SPAdes, HGAP74 and the
Celera-MHAP assembler.75
 Contigs can be visualised in the Java-based program Mauve (http://gel.Ahabs.Wisc.Edu/mauve/), which can also order and orientate contigs to a reference
genome. Alternatively, command-line tools such as MUMmer (http://mummer.Sourceforge.Net/) can be used to automate and batch this process as part of an
assembly pipeline.
Annotation
 Genome annotation includes identiﬁcation of DNA segments of known and probable open reading frames (ORF) that contain gene coding DNA, and matching
the identiﬁed segments to a database of known gene sequences. Tools include the web-based RAST (http://www.nmpdr.org/FIG/wiki/view.cgi/FIG/Rapid
AnnotationServer), NCBI’s Prokaryotic Genome Annotation Pipeline (http://www.ncbi.nlm.nih.gov/genome/annotation_prok/) or the command-line tool
Prokka (http://www.vicbioinformatics.com/software.prokka.shtml) for automated genome annotation.
Genome visualisation and comparison
 Once assembled and annotated, genomes can be viewed using a genome browser to display the structure and embedded genetic elements of a genome in a
graphical format, and manipulate the genome sequence if required. The Wellcome Trust Sanger Institute’s Artemis (http://www.sanger.ac.uk/resources/
software/artemis/), and the commercially available Geneious Pro suite (http://www.geneious.com/) are examples of genome browsers.
 Visual comparisons of multiple genomes can also be made using the above utilities.
Alignment and read mapping
 Read mapping is the process of aligning reads to a reference, using a combination of local and global alignment. Bowtie2 (http://bowtie-bio.sourceforge.
net/bowtie2/index.shtml) and BWA (http://bio-bwa.sourceforge.net/) are two of the more popular short read alignment algorithms.76
 BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi), the most widely used utility for searching a sequence database, uses local alignment of sequence segments.
BLAST can be run either as a web-based tool, or incorporated using a command line.
 Whole genome alignment is a computationally intensive process, but can be performed using Mauve or Mugsy/MUMmer (http://mugsy.sourceforge.net/).
SNP/variant calling
 Single nucleotide differences identiﬁed from aligning comparator sequences to a reference can be used to describe genetic relationships between isolates.
Multiple tools are available,77 and are frequently incorporated into more automated software packages.
 We use the Nesoni suite of tools (http://www.Vicbioinformatics.Com/software.Nesoni.Shtml) as well as SAMtools (http://samtools.Sourceforge.Net/),
Freebayes (https://github.Com/ekg/freebayes) and Nucmer (part of MUMmer).
Phylogenetic analysis
 Phylogenetic trees can be used to analyse and visualise the SNP differences between isolates, although the true phylogeny of a group of isolates is never known.
Popular methods include the simpler but rapid neighbour-joining method (most phylogenetic software), and the more complex maximum likelihood approach
(RAxML https://github.com/stamatak/standard-RAxML, and PhyML http://atgc.lirmm.fr/phyml/). More recently, Bayesian approaches to estimating phylogenetic
relationships have become popular as computation technology has improved. Examples include BEAST (http://beast2.org/), MrBayes (http://mrbayes.
sourceforge.net/), and BAPS (http://www.helsinki.ﬁ/bsg/software/).
 SplitsTree and FigTree are examples of phylogenetic software that can calculate neighbour-joining or display trees produced by other software.
Utilities for clinical microbiology
 Species identiﬁcation can be performed on WGS data by either 16 S characterisation, or by identifying short strings of DNA used in genome assembly (k-mer
identiﬁcation). Both options can be performed on the Danish Center for Genomic Epidemiology Java-based website http://www.genomicepidemiology.org/
 A number of other clinically useful tools are available on this site, including ResFinder for the detection of antimicrobial resistance, and Multi-Locus
Sequence Typing. Command-line based tools such as BLAST using de novo assemblies, or SRST2 (https://github.com/katholt/srst2)78 which uses read-mapping
on sequencing reads, are better suited to automation, batching of multiple sequence analyses, and incorporation into analysis pipelines.
Databases
 NCBI GenBank (http://www.ncbi.nlm.nih.gov/genbank) and Genome Bank (http://www.ncbi.nlm.nih.gov/genome)
 European Nucleotide Archive (http://www.ebi.ac.uk/ena)
 DNA Databank of Japan (http://www.ddbj.nig.ac.jp/)
Typing databases
 MLST database (http://www.mlst.net/databases/
Antibiotic resistance gene databases
 ARG-ANNOT (http://en.mediterranee-infection.com/article.php?laref=283&titre=arg-annot-)
 ResFinder (https://cge.cbs.dtu.dk/services/data.php)
Multifunction bioinformatic suites
 Geneious Pro (http://www.geneious.com/)
 CLC Genomics (http://www.clcbio.com/products/clc-genomics-workbench/)
 Bionumerics (http://www.applied-maths.com/bionumerics)
 Nesoni (http://www.vicbioinformatics.com/software.nesoni.shtml)
 Harvest (https://github.com/marbl/harvest)
 Galaxy (http://galaxyproject.org/)
A more extensive list of software can be found at http://seqanswers.com/wiki/Software/list.
204 KWONG et al. Pathology (2015), 47(3), April
Copyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.
(23%) or research-based professionals (3%). Respondents were
predominantly based in Victoria (34%) or New South Wales
(25%), although a number represented Western Australia (9%)
and New Zealand (8%).
Of respondents, 32% had some prior involvement withWGS,
although only 24% reported local capacity to perform WGS.
The Illumina MiSeq and the Ion Torrent PGM were the only
sequencers used. Although subject to survey bias, all respon-
dents indicated that they thought WGS would be useful in
clinical microbiology in the next 5–10 years, primarily for
epidemiological surveillance typing, clonality testing for out-
break investigation, and for detection of antimicrobial resist-
ance. Due to concerns about the cost of implementing and
conducting WGS, and the current lack of expertise in WGS and
bioinformatics, most respondents thought WGS would be most
likely used in reference laboratories, tertiary hospital labora-
tories and research laboratories. However, 83% thought that
WGS would be used at least once per month in their laboratory
over the next 5–10 years.
Although a qualitative study, this survey indicates a per-
ceived utility of WGS in clinical and public health micro-
biology, with realistic anticipation that in the current economic
climate, this will only be feasible in reference laboratories and
large tertiary hospitals. As others have alluded to,21,22 this
model, with a few peripheral nodes and a centralised hub for
WGS, would help to facilitate national/international collabor-
ation and standardisation.
WGS IN CLINICAL AND PUBLIC HEALTH
MICROBIOLOGY: HOW CAN IT HELP?
Structural and functional genomics
One of the primary investigation tools inmicrobial research is the
use of genomics to characterise an organism, including identi-
fication of the genetic elements that may result in pathogenicity,
survival, or antimicrobial resistance. As with human genetics,
microbial genomics has the capacity to interrogate organisms for
key genetic markers that may influence treatment and prognosis
of infections. Currently, there are four main potential appli-
cations of WGS for bacterial pathogen characterisation in the
diagnostic microbiology laboratory: identification, typing,
resistance detection, and virulence gene detection.
Identiﬁcation
Previous studies have illustrated proof-of-concept applications
using next-generation sequencing for bacterial identifi-
cation.23–28 Given the current costs of sequencing, this is
unlikely to surpass current methods such as matrix-assisted
laser desorption ionisation-time of flight (MALDI-TOF) for
routine bacterial detection for standard isolates. However,
WGS may play a key role with organisms that are unable to
be identified using routine methods. This includes organisms
that often undergo methods such as 16S rDNA sequencing or
specific nucleic acid probes to confirm identification, such as
Nocardia and non-tuberculous mycobacteria, and organisms
that are not usually or unable to be readily cultured. A recent
report of neuroleptospirosis diagnosed through next-generation
sequencing where conventional tests were non-diagnostic high-
lighted this potential role in diagnostic microbiology.23
Typing
Typing of bacterial pathogens for epidemiological surveillance,
infection control and outbreak investigation is a more obvious
and immediate application of WGS. There are numerous
traditional typing methods for several key organisms that are
generally performed in centralised reference laboratories,
although occasionally will be performed for a specific purpose
in routine diagnostic laboratories. For example, surveillance
typing of Listeria monocytogenes for outbreak monitoring has
been previously performed by a number of methods, including
serotyping, binary typing, ribotyping, multilocus variable num-
ber tandem repeat analysis (MLVA), pulse-field gel electro-
phoresis (PFGE), and multi-locus sequence typing (MLST).
Such diversity of methods with different resolution power is
difficult to maintain and may hinder rather than enhance strain
comparisons. Furthermore, typing is organism specific and
requires constant validation. In contrast, WGS has the capacity
to supersede traditional typing methods, through either in silico
typing, or superior discriminatory capacity.29,30 For instance,
MLST, which is traditionally performed by sequencing of a set
of housekeeping genes, can be simulated by mapping WGS
reads to the reference sequences of those genes,31 or using the
Basic Local Alignment Search Tool (BLAST) to identify the
alleles of the housekeeping genes.32 The role of WGS as a
superior method to typing for epidemiological surveillance and
outbreak investigation is described in the ‘Comparative geno-
mics’ section below.
Resistance detection
There are also potential applications for WGS to assist with
antimicrobial resistance detection. A few studies have attempted
to validate the accuracy of WGS for predicting antimicrobial
resistance, with reasonable concordance.20,33–35 Current
analyses using WGS data can readily detect acquired resistance
such as beta-lactamases and aminoglycoside modifying
enzymes, although characteristicmutations in critical genes such
as rpoB can also be detected with prediction of resistance
phenotypes. However, these methods are currently unable to
reliably predict some resistance mechanisms, for example,
resistance resulting from derepression of ampD, ampR and other
regulatory genes of AmpC hyperproduction, or vancomycin
heteroresistance conferred by mutations in the complex regulat-
ory system that includes graRS, vraSR, walKR, agr and rpoB.
Although current susceptibility methods from organism culture
are likely to bemore rapid and reliable for routine testing, as with
organism identification, WGS methods may be useful for slow-
growing organisms, organisms that are unable to be cultured, or
where phenotypic susceptibility testing is unreliable, e.g., clar-
ithromycin susceptibility testing for Mycobacterium abscessus.
For example, WGS was used to rapidly diagnose a case of
extensively drug-resistant (XDR) Mycobacterium tuberculosis,
reducing time to diagnosis from weeks to days, subsequently
reducing exposure to ineffective drugs andminimising risk of de
novo resistance.36
Virulence proﬁling
The other main potential use of WGS data for organism
characterisation is detection of genetic markers of virulence,
such as Panton-Valentine leukocidin (PVL) in Staphylococcus
aureus, or Shiga toxin in Escherichia coli, although this still
remains investigational due to the uncertainty in gene expres-
sion and significance of gene presence.37
Comparative genomics
The emergence of WGS as a universal replacement for
traditional bacterial typing has unveiled its potential as a
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powerful tool for epidemiological surveillance of bacterial
pathogens, one of the cornerstones of infection control. Although
largely performed in research environments, several studies have
illustrated the capabilities of WGS to describe the evolution and
epidemiology of important infections.38–46 In an era of increas-
ing antimicrobial resistance, mapping the epidemiology of such
multidrug resistant infections to direct public health responses
and antimicrobial prescribing practices is vital. In addition to
tracking resistant organisms, WGS allows tracking of specific
resistance mechanisms, including motifs on mobile genetic
elements such as plasmids and elucidation of mechanisms of
gene transfer.47,48 For example, Wright et al. demonstrated that
patients can be colonised with multiple strains of Acinetobacter
baumanii capable of interacting within the patient, and that
movement of patients and staff between healthcare facilities
contributes to strain mixing and diversification.49
There have been numerous studies reporting the use of WGS
to inform hospital infection control responses to suspected
pathogen transmission.50–58 In 2012, investigators from the
US National Institutes of Health (NIH) used WGS to track a
suspected outbreak of carbapenem-resistant Klebsiella pneu-
moniae, identifying a single patient as the source for three
independent transmission events.58 Another example was the
paradigm-shifting evidence fromWGS that multidrug-resistant
Mycobacterium abscessus subspecies massiliense was fre-
quently transmitted between patients with cystic fibrosis,
prompting reconsideration of infection control measures.50
The high discriminatory capacity of WGS has promoted it
as the new gold-standard method for strain comparison, sur-
passing more traditional typing methods for inferring disease
transmission and providing one of the strongest arguments for
the use of WGS in clinical and public health microbiology
laboratories.
Comparative genomic studies have also attempted to clarify
transmission events and outbreak propagation. These methods
relied upon established ‘molecular clocks’ to estimate the time
to the most common recent ancestor and dates of presumed
transmission events, using phylogenomic models.59 Some
defined thresholds for the number of SNPs between indepen-
dent isolates that are required to infer whether they are epide-
miologically linked,43,60 although mutation and recombination
rates vary between species and lineages,50 and the rates of
microevolution of endemic clones may need to be defined in
each context.
Culture-independent identiﬁcation and metagenomics
As alluded to above, WGS has been demonstrated to be a useful
tool as a culture-independent method of bacterial identification,
predominantly through metagenomic analyses. Although it is
yet to be implemented in routine diagnostics, metagenomics
involves sequencing all DNA content in a clinical sample,
before using bioinformatic analyses to filter out human and
non-pathogenic organism DNA to identify the causative agent.
Due to the extensive depth of sequencing required for species
identification, metagenomic investigations performed on low
diversity sterile site samples are likely to produce a greater
yield of results, in comparison to high diversity samples such as
faeces. High quality samples with sufficient concentrations of
genomic nucleic acid, such as tissue or fluid aspirates, are
paramount for this application of WGS.
Previous methods including broad-range 16S rRNA PCR and
sequencing have been used for diagnosis of culture-negative
bacterial infections.61 However, these methods frequently had
low sensitivity if insufficient pathogen DNA was present, and
were affected by the presence of contaminating DNA from
other bacterial species. Metagenomic analysis of WGS data
from a clinical sample has the capacity to overcome these
limitations by filtering out unwanted DNA in the post-sequen-
cing analysis. Sensitivity is also potentially greater, as organ-
isms can be identified from a number of different segments of
DNA, rather than a specific target segment which may have
been altered or fragmented in the pre-testing process.
Aside from research studies on the human microbiome, the
other potential application of metagenomics is in novel
pathogen discovery. Although it has been successful for identi-
fication of some pathogens,62,63 further testing is required to
confirm the validity of novel genomes discovered by next-
generation sequencing.64
Overall, metagenomic investigations remain experimental as
sequencing technology and bioinformatic software to process
and analyse metagenomic data is only just emerging.
CONSIDERATIONS FOR IMPLEMENTATION
Although WGS appears promising as an addition to the
armoury of tests that are currently used in clinical and public
health microbiology, it is yet to be widely implemented. With
the significant improvements in cost and ease of sequencing, it
is likely that WGS will supersede other molecular technologies
including PFGE, MLST, DNA microarray and 16S rDNA
sequencing in the near future, if not already. However, until
costs become negligible, it is unlikely to be adopted for routine
bacterial investigation over standard microscopy and culture,
MALDI-TOF identification, and phenotypic antimicrobial
susceptibility testing. Currently, the most immediately feasible
applications are typing, epidemiological surveillance, and out-
break investigation to inform infection control procedures,
most applicable to public health and tertiary hospital labora-
tories, although this would need to be matched by appropriate
bioinformatic expertise. This situation is dynamic, and likely to
change as sequencing technology evolves further and knowl-
edge of bioinformatics develops.
Limitations of WGS
There are limitations of WGS that should be recognised. At
present, the majority of analyses are based upon single nucleo-
tide variants or SNPs identified from comparisons to a refer-
ence genome sequence. Consequently, analyses are dependent
on the quality of sequencing and genome assembly, as well as
the quality and selection of the reference genome. As current
comparative analyses based on SNPs selectively exclude a
significant proportion of phylogenetic data, some bioinforma-
ticians have suggested conducting phylogenetic analyses based
on all loci in a genome, rather than limiting the analysis to
SNPs.65 However, the significant requirements in computation
resources and time would render such analyses unusable in a
clinical environment. In contrast to research applications,
comparative genomic methods for clinical purposes should
aim to utilise more time efficient estimations of phylogenetic
relationships that may not be the most accurate approximation,
but are of sufficient resolution and accuracy to inform clinical
and public health decisions.
AlthoughWGS data can be used to provide detailed genomic
information, this does not necessarily translate into knowledge
of gene expression and transcription. For example, the presence
of lukSF-PV does not necessarily equate to PVL production
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and/or clinically aggressive Staphylococcus aureus infection.
Detection of post-transcription RNA with next-generation
sequencing can be performed and may help detect gene expres-
sion or enzyme hyperproduction (e.g., BlaZ or AmpC beta-
lactamases), but requires a separate RNA sequencing run and is
unlikely to replace current phenotypic screening methods.
A major limitation of WGS in clinical laboratories is the lack
of validation and utility comparisons in clinical studies.
Although proof-of-concept studies are frequently published,
sequencing methods and data analyses for clinical projects have
been customised around selected pathogens. The development
and standardised evaluation of WGS pipelines for clinical and
public health laboratories would guide further widespread
implementation and add much needed evidence to an emerging
field.
Quality control and standardisation
As with all tests that are incorporated into diagnostic and public
health laboratory workflows, there is a need for a rigorous
quality control process and standardisation of testing. Such
measures have not yet been established, and benchmarks for
quality control are yet to be determined. What should be the
standard acceptable run quality? How should the quality of a
genome assembly be assessed? Based on Illumina sequencing,
we would recommend a minimum quality score of >30 across
the genome with a minimum depth of 30–50-fold (i.e., an
average of 30–50 overlapping reads at any particular locus) to
produce adequate quality sequence for clinical comparative
genomics. Although these have not been validated as the
optimal target sequencing metrics, they are consistent with
the recommendations recently proposed by the Australian
Public Health Laboratory Network.66 We currently interrogate
our read quality and genome assemblies manually, though this
is an arduous process for a large number of sequences that
might arise from an outbreak, and a standardised automated
quality control process is required. Figure 2 summarises some
of the key considerations when assessing quality of WGS
analyses.
National and international standardisation is also required,
particularly with comparative analyses. Decisions about which
reference genome is selected, or whether a composite reference
genome is used, or which typing method to correlate results
with each organism, need to be made at an overarching level
and accepted across sequencing sites nationally. However,
inter-site comparative analyses based on core genome SNPs
may also vary depending on the selection of test isolates. To
address this, the Global Microbial Identifier (GMI) initiative
requires individual sequencing sites to upload data to a cen-
tralised server, which updates real-time phylogenetic analyses
with the addition of new strains. An alternative solution has
been to use a globally standardised set of core genome house-
keeping genes to perform MLST, or whole-genome MLST
(wgMLST). This analysis involves typing based on approxi-
mately 2000 core genes for each species. At present, both
wgMLST and GMI are internationally-driven subscription
based services, and are yet to be globally accepted.
However, these methods can create ambiguity when infer-
ring direct pathogen transmission. Although wgMLST will
likely be useful as a high resolution typing tool, it excludes
a large amount of potentially informative genomic information,
such as phages, insertion sequences, and other mobile genetic
elements that may indicate direct transmission. A centralised
server that includes all strains and a constant reference genome
in comparative analyses can generate a phylogenetic signal, but
will frequently lack the resolution to infer transmission. As
there is frequently substantial genetic diversity within a single
species group, the number of core genes that are common to all
strains within that group diminishes as the number of strains
DNA extraction and
library
preparation
DNA quality
Correct fragment size distribution
•  Impacts overall data output
•  Impacts downstream analyses e.g. de novo assembly
Sufficient starting material
•  Adequate extraction from clinical samples and optimised
   extraction for different pathogens
Phred quality scores
•  Per base and per read sequence quality
•  Read trimming/clipping based on quality and length
Uniformity of genome coverage
•  Proportion of unique vs. overrepresented reads
•  GC bias; low coverage/problematic regions
Reference genome alignment
•  Appropriate reference genome selection
•  Per base mapping quality; unique/non-unique mapping
De novo assembly metrics
•  Number of contigs; N50; minimum contig length
•  Scaffolded assembly vs. closed genome
Criteria for variant calling/filtering
•  Whole genome vs. core genome
•  Consensus %; coverage depth; Per base quality etc.
Isolate genome subtyping and clustering
•  SNP-based vs. gene (e.g. wgMLST, pan-genome) based
•  Tree building algorithm with/without evolutionary models
DNA quantity
Quality of raw data
Sequence coverage
Read mapping
Assembly
Variant detection/
SNP calling
Similarity assessment
Sequencing
Data processing
Data analysis
Fig. 2 Key considerations in quality assessment of whole genome sequencing analyses. Contigs, contiguous sequences; GC, genome coverage; SNP, single nucleotide
polymorphism; wgMLST, whole genome multi-locus sequence typing.
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increases. Conversely, core genome analysis of a clonal sub-
population of that species group can involve many more
common genes, resulting in amplification of the number of
loci compared, and frequently the number of SNPs identified as
well. Thus, for identification of outbreak transmission, a refer-
ence genome should ideally be as similar to the outbreak strains
as possible, if not part of the outbreak, and comparative
genomic analyses should exclude outlying taxa that are not
suspected to be part of the outbreak.
A further consideration is at what level of similarity are two
isolates considered to be ‘identical’ or ‘related’ for inferring
disease transmission. In theory, immediate sampling of an
isolate that has been passed directly from Host A to Host B
should result in identical whole genome sequences with no
SNPs identifiable when the strains are directly compared to one
another. However, this rarely occurs, due to the background
mutation rate of organisms over time and the possible influ-
ences of sampling, storage and sequencing. Hence, it is difficult
to pre-specify a threshold that defines an outbreak strain from
one that is not. Within-host microbial genomic diversity has
also been demonstrated for a number of pathogens including
Klebsiella pneumoniae,58 Pseudomonas aeruginosa,67 Bur-
kholderia dolosa,68 and Staphylococcus aureus. In particular,
studies of S. aureus have demonstrated genetic diversity of up
to 40 SNPs between nasal isolates of the same spa-type and
MLST group from a single patient,69 as well as nasal carriage of
multiple strain types.70 Consequently, although appealing,
establishing a fixed threshold of genetic divergence for an
outbreak definition is difficult, and while comparative analyses
of genomic data can support epidemiological investigations,
they are not definitive.
Standardisation of data reporting is adopted to a certain
degree for other microbiological tests. However, with the detail
and complexity of genomic information, there are likely to be a
limited number of clinicians who are able to fully comprehend
and interpret all the data from a detailed analysis. Analogous to
continuous data variables, results may not be able to be con-
veyed as a simple dichotomous ‘yes’ or ‘no’ report. For
example, in an outbreak analysis, two isolates that differed
by 100 SNPs might not be considered related if other clustered
isolates were differing by 10 SNPs. However, if 90 of the 100
SNPs were co-located within a small genomic segment sug-
gestive of a recombination event, this may still represent
evidence of transmission. Lengthy technical descriptions of
possible interpretations are unhelpful, and there is a need to
develop standardised plain language reports, however there are
no studies to guide reporting methods.
Resource and infrastructure requirements
The relative financial costs of WGS are discussed above.
Additional costs for other equipment such as a high-end
fluorometer for assessing DNA quantity, and a bioanalyser
to assess DNA quality should be factored in. Fully automated
systems from DNA extraction, sample and library preparation
and sequencing have been marketed, although are rare. These
systems were developed to maximise efficiency and costs of
sequencing, but are geared more towards genomics reference
centres.
The post-sequencing bioinformatic costs can also be signifi-
cant. The emergence and accessibility of next-generation
sequencing has resulted in an exponential increase in the
amount of data generated from sequencing. The Illumina
MiSeq is able to generate up to 15 gigabytes of raw data every
3 days before post-sequencing processing, while the HiSeq can
generate up to one terabyte of data every week in high output
mode. Although some clinical microbiology laboratories have
previously invested in capacity for organism storage, physical
sequencing data storage with backup needs to be considered
with the implementation of WGS. Cloud-based storage options
have been proposed for both workflow and data storage,
however this may be impaired by bandwidth and data transfer
capabilities. Handling of data confidentiality, security and
integrity for these options also needs to be verified, though
storage of sequencing data would seem easier than frozen
organism storage.
Although many WGS analyses can be theoretically per-
formed on standard desktop computers, the computational
power required to process and analyse more than 50 genomes
in a clinically actionable timeframe is considerable. The
optimal specifications of this technology are beyond the scope
of this review, and require local expertise.
Comparisons with human genomics
As with bacteria, human DNA has also been sequenced in
research and clinical settings. While some parallels can be
drawn between human and microbial genomics, there are a
number of differences. The human genome is over 3 billion
base pairs in size, a thousand times the size of the average
bacterial genome. Somatic human cells are diploid with 23
pairs of chromosomes, while the majority of bacterial genomes,
if not haploid in genome content, behave in a haploid manner.
Several bacteria are polyploid organisms, e.g.,Neisseria gonor-
rhoeae, although the significance of this has not be determined.
Clinical human genomics has focussed on identifying
defined functional genetic mutations that result in disease.
With the size of the human genome, high throughput next-
generation sequencing has been used to perform targeted
capture sequencing of exomes (the collective protein-coding
regions of the genome) on large numbers of samples,71 repla-
cing previous DNA microarrays. Rapidly declining costs of
sequencing and improvement in sequencing technology has
resulted in greater utilisation of whole genome sequencing,
providing more comprehensive human genome data.
With the significant number of short reads required to
assemble the human genome, human WGS is more resource
intensive. For example, on Illumina’s NextSeq 500 in high
output mode, a single run can theoretically sequence the entire
genomes of up to 500 bacteria with an average genome size of 3
Mbp with 30 coverage. Alternatively, a single human genome
or up to 10 exomes can be sequenced with similar metrics.
There are also differences in post-sequencing bioinformatics.
Human genomics largely involves searching for defined
mutations in specific segments of DNA, although other
analyses such as genome wide association studies (GWAS)
have gained popularity to search for genetic markers of disease.
Assuming the most significant mutations occur in coding
regions, attention can be focussed on exome analysis. Adequate
coverage over these regions to ensure high sequence accuracy is
critical. In contrast, SNPs in non-coding regions can still be
informative to comparative bacterial phylogenomics. Detection
of small indels is essential to identify mutations in the human
genome, but is not always required for bacterial outbreak
investigation. While detection of recombination in bacterial
genomes is important to identify horizontal genetic exchange
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and improve phylogenetic signal, such analyses are more of
interest in the evolution of the human genome, rather than
informing clinical human genetics.
Given these important differences, it follows that different
expertise is required for human and bacterial genomics, and
although there are similarities that may allow some sharing of
certain resources such as a sequencing platform and reagents,
each requires a different sequencing and bioinformatics con-
figuration.
FUTURE DIRECTIONS
Whole genome sequencing has undisputed applications in
research to enhance our understanding in numerous facets of
infectious diseases and microbiology. Research into these
aspects, including pathogen evolution, epidemiology and viru-
lence determinants, and development and spread of antimicro-
bial resistance mechanisms, indirectly influences microbiology
and clinical infectious diseases practices, and has the ultimate
goal of improving patient care. Genomics is also increasingly
being used in identifying potential drug and vaccine targets, and
the increasing use of metagenomic analyses are starting to build
our understanding of microbial ecosystems including the
human microbiome.
There are still limitations that hinder widespread imple-
mentation of WGS in clinical and public health microbiology
as a test performed in real-time to directly inform clinical
practices. Even with rapidly improving sequencing efficiency,
WGS is unlikely to surpass current methods for routine bac-
terial identification and antimicrobial susceptibility testing in
the near future. It would seemingly have an expanding role in
public health, reference and infection control laboratories for
detailed isolate characterisation, outbreak investigation, and
detection of disease transmission. As sequencing becomes
more widely available and utilised, more routine use in diag-
nostic laboratories for pathogen identification in culture-nega-
tive samples, and metagenomic investigation of polymicrobial
samples for pathogen and ‘resistome’ identification may be
adopted.
It is clear that user-friendly bioinformatic pipelines are key to
facilitating more widespread use of WGS, with more wide-
spread bioinformatics expertise. Until this bottleneck is over-
come, the most immediate implementation strategy is for
centralised state reference laboratories to perform WGS and
data analysis, with peripheral centres outsourcing to the refer-
ence laboratories as required. As uptake of WGS improves and
costs decline, a more powerful epidemiological surveillance
system could be established with sequencing performed at
peripheral nodes, with bioinformatic analysis and oversight
of the sequencing at the centralised reference centre. In an era
of increasing drug resistance globally, ease of international
travel, and little investment into antimicrobial drug develop-
ment, utilising the few but powerful tools we have available to
monitor and curb the spread of infectious diseases is para-
mount.
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